IP Library Patent Application 10508781
Patent Application
App. No. 10/508,781

Serum biomarkers in hepatocellular carcinoma

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/508,781
Abstract

Certain biomarkers and biomarker combinations are useful in a qualifying hepatocellular carcinoma status in a patient. A diagnostic methodology employing these biomarkers and combinations can distinguish between hepatocellular carcinoma and chronic liver disease, for example.

Claims (41)

1 . A method for qualifying hepatocellular carcinoma status in a subject, comprised of analyzing a biological sample from said subject for a diagnostic level of a protein selected from a first group consisting of

(A) I-M1, I-M2, I-M3, I-M4, I-M5, I-M6, I-M7, I-M8, I-M9, I-M10, I-M11, I-M12, I-M13, I-M14, I-M15, I-M16, I-M17, I-M18, I-M19, I-M20, I-M21, I-M22, I-M23, I-M24, I-M25, I-M26, I-M27, I-M28, I-M29, I-M30, I-M31, I-M32, I-M33, I-M34, I-M35, I-M36, I-M37, I-M38, I-M39, I-M40, I-M41, I-M42, I-M43, I-M44, I-M45, I-M46, I-M47, I-M48, I-M49, I-M50, I-M51, I-M52, I-M53, I-M54, I-M55, I-M56, I-M57, I-M58, I-M59, I-M60, I-M61, I-M61, I-M62, I-M63, I-M64, I-M65, I-M66, I-M67, I-M68, I-M69, I-M70, I-M71, I-M72, I-M73, I-M74, I-M75, I-M76, I-M77, I-M79, I-M80, I-M81, I-M82, I-M83, I-M84, I-M85, I-M86, I-M87, I-M88, I-M89, I-M90, I-M91, I-M92, I-M93, I-M94, I-M95, I-M96, I-M97, I-M98, I-M99, I-M100

and/or a second group consisting of

(B) W-M1, W-M2, W-M3, W-M4, W-M5, W-M6, W-M7, W-M8, W-M9, W-M10, W-M11, W-M12, W-M13, W-M14, W-M15, W-M16, W-M17, W-M18, W-M19, W-M20, W-M21, W-M22, W-M23, W-M24, W-M25, W-M26, W-M27, W-M28, W-M29, W-M30, W-M31, W-M32, W-M33, W-M34, W-M35, W-M36, W-M37, W-M38, W-M39, W-M40, W-M41, W-M42, W-M43, W-M44, W-M45, W-M46, W-M47, W-M48, W-M49, W-M50, W-M51, W-M52, W-M53, W-M54, W-M55, W-M56, W-M57, W-M58, W-M59, W-M60, W-M61, W-M61, W-M62, W-M63, W-M64, W-M65, W-M66, W-M67, W-M68, W-M69, W-M70, W-M71, W-M72, W-M73, W-M74, W-M75, W-M76, W-M77, W-M79, W-M80, W-M81, W-M82, W-M83, W-M84, W-M85, W-M86, W-M87, W-M88, W-M89, W-M90, W-M91, W-M92, W-M93, W-M94, W-M95, W-M96, W-M97, W-M98, W-M99, W-M100,

wherein said level is elevated relative to a norm.

2 . A method for qualifying hepatocellular carcinoma status in a patient according to claim 1 , wherein said protein is selected from the group consisting of

(A) I-M1, I-M3, I-M4, I-M5, I-M6, I-M7, I-M9, I-M11, I-M12, I-M13, I-M18, I-M19, I-M20, I-M21, I-M22, I-M23, I-M25, I-M26, I-M28, I-M32, I-M34, I-M36, I-M37, I-M41, I-M44, I-M46, I-M47, I-M52, I-M53, I-M64, I-M68, I-M69, I-M77, I-M79, I-M81, I-M84, I-M87, I-M88, I-M89, and I-M92

and/or a second group consisting of

(B) W-M1, W-M2, W-M3, W-M4, W-M5, W-M7, W-M9, W-M10, W-M11, W-M12, W-M13, W-M14, W-M15, W-M16, W-M17, W-M18, W-M19, W-M20, W-M21, W-M22, W-M23, W-M25, W-M26, W-M27, W-M30, W-M31, W-M33, W-M34, W-M35, W-M36, W-M39, W-M40, W-M41, W-M43, W-M44, W-M46, W-M47, W-M48, W-M49, W-M50, W-M52, W-M53, W-M54, W-M55, W-M58, W-M60, W-M62, W-M63, W-M70, W-M71, W-M73, W-M76, W-M78, W-M84, W-M86, W-M88, W-M89, W-M90, W-M93, W-M95, W-M96, W-M98, and W-M100.

3 . A method according to claim 2 , wherein said protein is I-M13, I-M18, I-M19, W-M2, or W-M23.

4 . A method for qualifying hepatocellular carcinoma risk in a patient, comprising

(A) providing a spectrum generated by mass spectroscopic analysis of a biological sample taken from the subject, and

(B) extracting data from the spectrum and subjecting the data to pattern-recognition analysis that is keyed to at least one peak selected from

a first group consisting of

(i) I-M1, I-M3, I-M4, I-M5, I-M6, I-M7, I-M9, I-M11, I-M12, I-M13, I-M18, I-M19, I-M20, I-M21, I-M22, I-M23, I-M25, I-M26, I-M28, I-M32, I-M34, I-M36, I-M37, I-M41, I-M44, I-M46, I-M47, I-M52, I-M53, I-M64, I-M68, I-M69, I-M77, I-M79, I-M81, I-M84, I-M87, I-M88, I-M89, and I-M92,

and/or a second group consisting of

(ii) W-M1, W-M2, W-M3, W-M4, W-M5, W-M7, W-M9, W-M10, W-M11, W-M12, W-M13, W-M14, W-M15, W-M16, W-M17, W-M18, W-M19, W-M20, W-M21, W-M22, W-M23, W-M25, W-M26, W-M27, W-M30, W-M31, W-M33, W-M34, W-M35, W-M36, W-M39, W-M40, W-M41, W-M43, W-M44, W-M46, W-M47, W-M48, W-M49, W-M50, W-M52, W-M53, W-M54, W-M55, W-M58, W-M60, W-M62, W-M63, W-M70, W-M71, W-M73, W-M76, W-M78, W-M84, W-M86, W-M88, W-M89, W-M90, W-M93, W-M95, W-M96, W-M98, and W-M100.

5 . A method according to claim 4 , wherein said pattern-recognition analysis is keyed to a pair of peaks selected from

(A) I-M13 and I-M25, I-M13 and I-M7, I-M25 and I-M46, I-M37 and I-M77, I-M5 and I-M36, and/or

(B) W-M14 and W-M98, W-M21 and W-M46, W-M11 and W-M52, W-M16 and W-M89, W-M1 and W-M46, W-M21 and W-M76, W-M11 and W-M33, W-M13 and W-M18, W-M2 and W-M46, W-M33 and W-M54, W-M2 and W-M46, W-M16 and W-M46, W-M11 and W-M5.

6 . A method according to claim 4 , wherein said pattern-recognition analysis is keyed to a triplet of peaks selected from

(A) I-M1, I-M4 and I-M36; I-M5, I-M7 and I-M19; I-M7, I-M19 and I-M46; I-M9, I-M34 and I-M52; I-M7, I-M18 and I-M47; I-M11, I-M13 and I-M36; I-M9, I-M77 and I-M84; and [-M18, I-M22 and I-M79, and/or

(B) W-M21, W-M22 and W-M35; W-M7, W-M21 and W-M46; W-M13, W-M14 and W-M98; W-M14, W-M54 and W-M70; W-M11, W-M33 and W-M46; W-M17, W-M36 and W-M98; W-M19, W-M21 and W-M22; W-M14, W-M15, W-M54; W-M55, W-M58 and W-M98; W-M11, W-M14 and W-M98; W-M1, W-M33 and W-M46; W-M40, W-M46 and W-M49; W-M15, W-M21 and W-M22; W-M14, W-M36 and W-M98; W-M5, W-M11 and W-M54; W-M14, W-M22 and W-M25; W-M14, W-M58 and W-M98; W-M5, W-M14 and W-M89; W-M7, W-M14 and W-M89; W-M14, W-M21 and W-M98; W-M11, W-M58 and W-M71; W-M14, W-M25 and W-M54; W-M14, W-M60 and W-M89; W-M21, W-M46 and W-M100.

7 . A method according to claim 4 , wherein said pattern-recognition analysis is keyed to a combination of peaks selected from

(A) I-M11, I-M13, I-M19 and I-M89; I-M13, I-M19, I-M22 and I-M26; I-M1, I-M5, I-M36 and I-M41; I-M19, I-M33, I-M44 and I-M46; I-M3, I-M18, I-M68 and I-M81; I-M3, I-M12, I-M34 and I-M81; I-M12, I-M13, I-M32 and I-M37; I-M18, I-M44, I-M46 and I-M79; I-M7, I-M13, I-M21 and I-M23; I-M3, I-M18, I-M77 and I-M92; I-M12, I-M13, I-M77 and I-M87; I-M6, I-M13, I-M34 and I-M81; I-M8, I-M19, I-M53, I-M64, I-M69; I-M4, I-M18, I-M28, I-M47 and I-M88; and I-M1, I-M4, I-M18, I-M36, I-M41 and I-M47, and/or

(B) W-M25, W-M55, W-M62 and W-M98; W-M7, W-M14, W-M17 and W-M89; W-M17, W-M31, W-M93 and W-M98; W-M11, W-M19, W-M46 and W-M50; W-M4, W-M33, W-M55 and W-M98; W-M5, W-M11, W-M36 and W-M54; W-M16, W-M36, W-M43 and W-M46; W-M11, W-M41, W-M54 and W-M73; W-M5, W-M11, W-M52 and W-M89; W-M4, W-M14, 58 and W-M89; W-M2, W-M12, W-M14, W-M89; W-M5, W-M11, W-M20 and W-M40; W-M21, W-M46, W-M70 and W-M88; W-M21, W-M33, W-M34 and W-M46; W-M17, W-M20, W-M40 and W-M58; W-M17, W-M33, W-M52 and W-M98; W-M3, W-M7, W-M21 and W-M46; W-M10, W-M22, W-M30 and W-M95; W-M1, W-M46, W-M54 and W-M70; W-M11, W-M14, W-M25 and W-M54; W-M11, W-M33, W-M46 and W-M90; W-M11, W-M14, W-M54 and W-M89; W-M7, W-M18, W-M21 and W-M22; W-M17, W-M20, W-M52 and W-M98; W-M2, W-M15, W-M19, W-M22 and W-M55; W-M17, W-M19, W-M26, W-M47 and W-M98; W-M9, W-M11, W-M27, W-M46 and W-M78; W-M5, W-M11, W-M33, W-M46 and W-M53; W-M2, W-M9, W-M15, W-M19 and W-M89; W-M5, W-M11, W-M52, W-M89 and W-M96; W-M16, W-M25, W-M40, W-M52 and W-M89; W-M14, W-M15, W-M21, W-M22 and W-M89; W-M5, W-M13, W-M16, W-M20 and W-M98; W-M9, W-M23, W-M26, W-M40 and W-M89; W-M20, W-M27, W-M30, W-M35, W-M40 and W-M70; W-M13, W-M26, W-M39, W-M44, W-M63 and W-M98; W-M5, W-M13, W-M35, W-M39, W-M86 and W-M89; and W-M3, W-M18, W-M21, W-M22, W-M48, and W-M84.

8 . A kit for detecting and diagnosing hepatocelluar carcinoma, comprising

(A) an adsorbent attached to a substrate that retains one or more of the biomarkers selected from either a first group consisting of

(i) I-M1, I-M2, I-M3, I-M4, I-M5, I-M6, I-M7, I-M8, I-M9, I-M10, I-M11, I-M12, I-M13, I-M14, I-M15, I-M16, I-M17, I-M18, I-M19, I-M20, I-M21, I-M22, I-M23, I-M24, I-M25, I-M26, I-M27, I-M28, I-M29, I-M30, I-M31, I-M32, I-M33, I-M34, I-M35, I-M36, I-M37, I-M38, I-M39, I-M40, I-M41, I-M42, I-M43, I-M44, I-M45, I-M46, I-M47, I-M48, I-M49, I-M50, I-M51, I-M52, I-M53, I-M54, I-M55, I-M56, I-M57, I-M58, I-M59, I-M60, I-M61, I-M61, I-M62, I-M63, I-M64, I-M65, I-M66, I-M67, I-M68, I-M69, I-M70, I-M71, I-M72, I-M73, I-M74, I-M75, I-M76, I-M77, I-M79, I-M80, I-M81, I-M82, I-M83, I-M84, I-M85, I-M86, I-M87, I-M88, I-M89, I-M90, I-M91, I-M92, I-M93, I-M94, I-M95, I-M96, I-M97, I-M98, I-M99, I-M100

or a second group consisting of

(ii) W-M1, W-M2, W-M3, W-M4, W-M5, W-M6, W-M7, W-M8, W-M9, W-M10, W-M11, W-M12, W-M13, W-M14, W-M15, W-M 16, W-M17, W-M18, W-M19, W-M20, W-M21, W-M22, W-M23, W-M24, W-M25, W-M26, W-M27, W-M28, W-M29, W-M30, W-M31, W-M32, W-M33, W-M34, W-M35, W-M36, W-M37, W-M38, W-M39, W-M40, W-M41, W-M42, W-M43, W-M44, W-M45, W-M46, W-M47, W-M48, W-M49, W-M50, W-M51, W-M52, W-M53, W-M54, W-M55, W-M56, W-M57, W-M58, W-M59, W-M60, W-M61, W-M61, W-M62, W-M63, W-M64, W-M65, W-M66, W-M67, W-M68, W-M69, W-M70, W-M71, W-M72, W-M73, W-M74, W-M75, W-M76, W-M77, W-M79, W-M80, W-M81, W-M82, W-M83, W-M84, W-M85, W-M86, W-M87, W-M88, W-M89, W-M90, W-M91, W-M92, W-M93, W-M94, W-M95, W-M96, W-M97, W-M98, W-M99, W-M100,

(B) instructions to detect the biomarker(s) by contacting a sample with the adsorbent and detecting the biomarker(s) retained by the adsorbent.

9 . A kit according to claim 8 , further comprising a washing solution or instructions for making a washing solution.

10 . A kit according to claim 8 , wherein the substrate is a SELDI probe that comprises either (i) functionalities that adsorb transition metal ions by chelation or (ii) functionalities that allow for cation exchange.

11 . Software for qualifying hepatocellular carcinoma status in a subject, comprising an algorithm for analyzing data extracted from a spectrum generated by mass spectroscopic analysis of a biological sample taken from the subject, wherein said data relates to one or more biomarkers selected from either a first group consisting of

(i) I-M1, I-M2, I-M3, I-M4, I-M5, I-M6, I-M7, I-M8, I-M9, I-M10, I-M11, I-M12, I-M13, I-M14, I-M15, I-M16, I-M17, I-M18, I-M19, I-M20, I-M21, I-M22, I-M23, I-M24, I-M25, I-M26, I-M27, I-M28, I-M29, I-M30, I-M31, I-M32, I-M33, I-M34, I-M35, I-M36, I-M37, I-M38, I-M39, I-M40, I-M41, I-M42, I-M43, I-M44, I-M45, I-M46, I-M47, I-M48, I-M49, I-M50, I-M51, I-M52, I-M53, I-M54, I-M55, I-M56, I-M57, I-M58, I-M59, I-M60, I-M61, I-M61, I-M62, I-M63, I-M64, I-M65, I-M66, I-M67, I-M68, I-M69, I-M70, I-M71, I-M72, I-M73, I-M74, I-M75, I-M76, I-M77, I-M79, I-M80, I-M81, I-M82, I-M83, I-M84, I-M85, I-M86, I-M87, I-M88, I-M89, I-M90, I-M91, I-M92, I-M93, I-M94, I-M95, I-M96, I-M97, I-M98, I-M99, I-M100

or a second group consisting of

(ii) W-M1, W-M2, W-M3, W-M4, W-M5, W-M6, W-M7, W-M8, W-M9, W-M10, W-M11, W-M12, W-M13, W-M14, W-M15, W-M16, W-M17, W-M18, W-M19, W-M20, W-M21, W-M22, W-M23, W-M24, W-M25, W-M26, W-M27, W-M28, W-M29, W-M30, W-M31, W-M32, W-M33, W-M34, W-M35, W-M36, W-M37, W-M38, W-M39, W-M40, W-M41, W-M42, W-M43, W-M44, W-M45, W-M46, W-M47, W-M48, W-M49, W-M50, W-M51, W-M52, W-M53, W-M54, W-M55, W-M56, W-M57, W-M58, W-M59, W-M60, W-M61, W-M61, W-M62, W-M63, W-M64, W-M65, W-M66, W-M67, W-M68, W-M69, W-M70, W-M71, W-M72, W-M73, W-M74, W-M75, W-M76, W-M77, W-M79, W-M80, W-M81, W-M82, W-M83, W-M84, W-M85, W-M86, W-M87, W-M88, W-M89, W-M90, W-M91, W-M92, W-M93, W-M94, W-M95, W-M96, W-M97, W-M98, W-M99, W-M100,

12 . Software according to claim 11 , wherein said algorithm carries out a pattern-recognition analysis that is keyed to data relating to at least one of the biomarkers.

13 . Software according to claim 12 , wherein said algorithm comprises classification tree analysis that is keyed to data relating to at least one of the biomarkers.

14 . Software according to claim 12 , wherein said algorithm comprises artificial neural network analysis that is keyed to data relating to at least one of the biomarkers

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 25, 2015
From: QUEST DIAGNOSTICS INCORPORATED
To: VERMILLION, INC. (F/K/A CIPHERGEN BIOSYSTEMS, INC.)
Reel/Frame 035256/0457 →
CHANGE OF NAME Recorded Nov 14, 2007
From: CIPHERGEN BIOSYSTEMS INC.
To: VERMILLION, INC.
Reel/Frame 020108/0309 →
SECURITY INTEREST Recorded Mar 20, 2006
From: CHIPHERGEN BIOSYSTEMS, INC.
To: QUEST DIAGNOSTICS INCORPORATED
Reel/Frame 017345/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2005
From: POON, TERENCE C. W.; JOHNSON, PHILIP; CHAN, ANTHONY
To: CHINESE UNIVERSITY OF HONK KONG, THE
Reel/Frame 016811/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2005
From: YIP, TAI-TUNG; YIP, VICTOR; YIP, CHRISTINE
To: CIPHERGEN BIOSYSTEMS, INC.
Reel/Frame 016813/0385 →